INTRODUCTION {#uog19047-sec-0005}
============

Patients with pulmonary atresia with intact ventricular septum (PAIVS) or critical pulmonary stenosis (CPS) carry a significant risk of morbidity and mortality[1](#uog19047-bib-0001){ref-type="ref"}. During fetal life, progression of CPS and development of PAIVS have been reported[2](#uog19047-bib-0002){ref-type="ref"}, [3](#uog19047-bib-0003){ref-type="ref"}. In the absence of high‐grade tricuspid regurgitation (TR) this lesion leads to a hypoplastic right ventricle (RV), which may preclude a biventricular circulation after birth[1](#uog19047-bib-0001){ref-type="ref"}, [4](#uog19047-bib-0004){ref-type="ref"}, [5](#uog19047-bib-0005){ref-type="ref"}. Even if biventricular repair can be achieved postnatally, RV function may remain abnormal and the potential of postnatal RV growth is limited[6](#uog19047-bib-0006){ref-type="ref"}, [7](#uog19047-bib-0007){ref-type="ref"}. Therefore, the goal of fetal pulmonary valvuloplasty is to stimulate and promote prenatal RV growth in order to avoid significant RV hypoplasia at birth. It has been shown that the fetal myocardium responds to increased pre‐ and afterload with hyperplasia, in contrast to hypertrophy after birth. Therefore, prenatal treatment could be a unique opportunity to take advantage of a better ventricular growth than that achievable postnatally. A few case reports and small case series have shown that fetal pulmonary valvuloplasty is technically feasible and associated with continued growth of RV structures[8](#uog19047-bib-0008){ref-type="ref"}, [9](#uog19047-bib-0009){ref-type="ref"}, [10](#uog19047-bib-0010){ref-type="ref"}, [11](#uog19047-bib-0011){ref-type="ref"}, [12](#uog19047-bib-0012){ref-type="ref"}, [13](#uog19047-bib-0013){ref-type="ref"}. The International Fetal Cardiac Intervention Registry reported 16 fetal pulmonary valvuloplasties, of which 11 procedures were successful and resulted in seven liveborn patients, five of which were discharged with a biventricular circulation. However, no data on preprocedure RV dimensions or postprocedure RV growth were recorded in these reports[13](#uog19047-bib-0013){ref-type="ref"}.

The aim of this study was to assess the immediate effects of fetal pulmonary valvuloplasty on RV size and function as well as *in‐utero* RV growth and postnatal outcome in fetuses with PAIVS or CPS.

METHODS {#uog19047-sec-0006}
=======

All patients who underwent fetal pulmonary valvuloplasty at our center between October 2000 and July 2017 were included in this study. Criteria for fetal pulmonary valvuloplasty were either membranous atresia or a critical stenosis of the pulmonary valve (PV) with a recognizable RV outflow tract (RV‐OT), retrograde flow in the ductus arteriosus and a hypoplastic hypertrophic RV with suprasystemic pressures as assessed by the velocity of the TR jet. Exclusion criteria were muscular atresia of the RV‐OT, severe TR with low velocity (\< 2.5 m/s) or the presence of large RV sinusoids. The study was approved by our local ethics committee (study number K‐104‐16) and informed consent was not required.

All patients had an echocardiographic examination (Vivid 7®, Vivid E9®, Vivid E95®; GE Medical Systems, Zipf, Austria) a few days before and after the procedure (median interval after intervention, 1 (range, 1--3) days) by the same experienced echocardiographer (G.T.). Two‐dimensional and Doppler echocardiographic data were recorded and stored on video tape (prior to 2010) or in digital format (Echopac®, GE Medical Systems). Echocardiographic data were analyzed retrospectively for ventricular and valvular dimensions and ratios, as well as for RV filling time (duration of tricuspid valve (TV) inflow/cardiac cycle length), TV velocity time integral (TV‐VTI) × heart rate (HR), and TR velocity.

All interventions were performed under ultrasound guidance as described previously[8](#uog19047-bib-0008){ref-type="ref"}, [14](#uog19047-bib-0014){ref-type="ref"} and under general anesthesia of the mother without separate fetal analgesia. The fetal RV was punctured with a 16‐, 18‐ or 19‐gauge needle (Cook® Medical Systems, Limerick, Ireland). A 3‐, 5‐ or 4‐mm coronary balloon catheter (Maverick®, Boston Scientific, Vienna, Austria) was used for valve dilatation. The balloon‐to‐valve ratio was aimed at between 1 and 1.5; however, balloon size was limited by the inner diameter of the needle. Eight patients had two and two patients had three procedures due to technical failure of the first attempts. A procedure was considered successful if the PV was perforated and/or passed and dilated with a balloon catheter. A partially successful procedure was defined as one in which the PV was perforated and passed, but the valve was not dilated with the full diameter of the balloon.

Patients\' charts were reviewed for postnatal procedures and outcome. Biventricular outcome was defined as a circulation in which the RV was the only source of pulmonary blood flow in the absence of any signs of right‐heart failure. Undetermined circulation was one in which a modified Blalock--Taussig (BT) shunt or ductal stent was placed postnatally and the final circulation was still unclear. Eight patients were delivered and treated in our center, whereas all other patients were delivered and managed in their respective home countries. For the longitudinal assessment of RV growth, only measurements from fetuses that were delivered and followed up at our center were used.

To assess the effect of fetal pulmonary valvuloplasty on outcome, patients were grouped retrospectively according to the scoring system published by Roman *et al*.[15](#uog19047-bib-0015){ref-type="ref"}. This scoring system is based on four parameters (TV/mitral valve annular diameter (TV/MV) ratio \< 0.7, RV/left ventricle length (RV/LV) ratio \< 0.6, RV filling time \< 31.5% of cardiac cycle length and presence of RV sinusoids), with 100% sensitivity and 75% specificity predicting a non‐biventricular outcome if three of these four criteria are fulfilled. High‐quality data were available for 20/23 patients: 10 patients had a score of three, four had a score of two, two a score of one and four patients had a score of zero.

Significant changes in RV function and dimensions before and after intervention were evaluated using paired *t*‐tests. Statistical significance was considered as *P* ≤ 0.05. Fetal cardiac *Z*‐scores were obtained using a statistical program (Cardio Z; UBQO, Evelina Children\'s Hospital, London, UK). Data are expressed as median with range, unless stated otherwise.

RESULTS {#uog19047-sec-0007}
=======

Between October 2000 and July 2017, a total of 129 fetal intracardiac interventions were performed in 108 patients at our center. Of these, 35 procedures were fetal pulmonary valvuloplasties which were carried out on 23 fetuses with PAIVS (*n* = 15) or CPS (*n* = 8). Most interventions (31/35) took place after January 2010. Median gestational age at the time of intervention was 28 + 4 (range, 23 + 6 to 32 + 1) weeks. Patients were referred from nine different countries. Baseline echocardiographic measurements of the patients are presented in Table [1](#uog19047-tbl-0001){ref-type="table"}.

###### 

Cardiac measurements, before intervention, of 23 fetuses with pulmonary atresia with intact ventricular septum or critical pulmonary stenosis, that underwent fetal pulmonary valvuloplasty

  Parameter                                                 *n* [\*](#uog19047-note-0001){ref-type="fn"}    Value (median (range))
  -------------------------------------------------------- ---------------------------------------------- ---------------------------
  RV/LV ratio                                                                    19                           0.57 (0.47 to 0.70)
  TV/MV ratio                                                                    19                           0.69 (0.62 to 0.97)
  RV filling time[†](#uog19047-note-0002){ref-type="fn"}                         19                           0.28 (0.19 to 0.42)
  RV length *Z*‐score                                                            18                        --2.95 (--4.64 to --1.33)
  TV annular diameter *Z*‐score                                                  18                         --1.77 (--3.52 to 0.39)
  TR Vmax (m/s)                                                                  19                           4.83 (3.28 to 5.5)
  TV‐VTI × HR (cm × bpm)                                                         18                          821.5 (287.5 to 1859)

Data not available in all cases.

Duration of tricuspid valve (TV) inflow indexed to cardiac cycle length.

HR, heart rate; RV, right ventricular; RV/LV ratio, right to left ventricular length ratio; TR Vmax, maximum velocity of tricuspid regurgitation; TV/MV ratio, tricuspid to mitral valve annular diameter ratio; TV‐VTI, tricuspid valve velocity time integral.

Seventeen patients had a technically successful and four a partially successful procedure (91.3%). The procedure itself was successful in 22/35 (62.9%) interventions. Individual patient data regarding cardiac anatomy and procedural details, complications and outcome are listed in Table [2](#uog19047-tbl-0002){ref-type="table"}.

###### 

Procedure details, complications and outcome of fetal pulmonary valvuloplasty (FPV) performed on 23 fetuses with pulmonary atresia with intact ventricular septum (PAIVS) or critical pulmonary stenosis (CPS)

  Case                                         Cardiac anatomy   GA at FPV (weeks)   Year of FPV   FPV attempts (*n*)   GA at subsequent FPV(s) (weeks)   Technical success   Balloon/valve ratio   Pericardial effusion n.t.   Bradycardia n.t.   Prediction score[\*](#uog19047-note-0003){ref-type="fn"} before FPV   PV gradient (Vmax) after FPV (m/s)   GA at birth (weeks)                                              Postnatal procedure(s)                                               Circulation    Follow‐up (years)
  ------------------------------------------- ----------------- ------------------- ------------- -------------------- --------------------------------- ------------------- --------------------- --------------------------- ------------------ --------------------------------------------------------------------- ------------------------------------ --------------------- --------------------------------------------------------------------------------------------------------------- -------------- -------------------
  1[†](#uog19047-note-0004){ref-type="fn"}          PAIVS             27 + 6            2000               1                          ---                         Y                   1.0                       N                      Y                                            3                                                    ND                         37 + 6                                 PV dilatation, modified BT shunt, BT shunt removal at 9 months                                BV              16.36
  2                                                  CPS              24 + 0            2003               1                          ---                         N                   ---                       N                      N                                           ND                                                   ---                         32 + 0                                                        Modified BT shunt                                                      UV               NND
  3[†](#uog19047-note-0004){ref-type="fn"}          PAIVS             32 + 1            2007               2                        31 + 2                        Y                   ND                        N                      N                                           ND                                                    ND                         37 + 1                                   PV dilatation, modified BT shunt, BDG and RVOT enlargement                                1.5 V             9.28
  4                                                  CPS              28 + 5            2010               1                          ---                         Y                   1.0                       N                      N                                            3                                                   3.1                         40 + 3                         PV dilatation, RVOT patch, PV valvotomy and modified BT shunt, coiling BT shunt                       BV              7.16
  5                                                  CPS              29 + 3            2010               1                          ---                         Y                   1.0                       N                      N                                            0                                                   4.4                         38 + 3                                                          PV dilatation                                                        BV              6.82
  6[†](#uog19047-note-0004){ref-type="fn"}          PAIVS             25 + 0            2012               1                          ---                         Y                   1.1                       N                      N                                            3                                                   1.3                         37 + 1                                        Valvotomy and modified BT shunt, coiling BT shunt                                      BV              4.78
  7                                                 PAIVS             31 + 0            2013               1                          ---                         N                   ---                       N                      N                                            3                                                   ---                           ND                                 Modified BT shunt followed by BDG anastomosis and Fontan procedure                              UV               LFU
  8                                                  CPS              26 + 6            2013               2                        25 + 4                     Partial                1.0                       N                      N                                            3                                                   2.1                         35 + 1                                       Modified BT shunt, PV dilatation, BDG and RPA patch                                   1.5 V             3.56
  9                                                 PAIVS             25 + 5            2014               1                          ---                         Y                   0.9                       N                      N                                            3                                                   3.5                         40 + 4                                                       PV dilatation (4×)                                                      BV              2.40
  10                                                PAIVS             28 + 5            2014               1                          ---                         Y                   1.1                       Y                      Y                                            2                                                   2.1                         37 + 5                                                          PV dilatation                                                        BV              2.75
  11[†](#uog19047-note-0004){ref-type="fn"}          CPS              29 + 3            2015               1                          ---                         Y                   0.9                       Y                      N                                            0                                                   2.2                         39 + 1                                                          PV dilatation                                                        BV              1.81
  12                                                PAIVS             27 + 5            2015               2                        27 + 0                        Y                   0.8                       N                      Y                                            3                                                   3.3                         39 + 1                                 Radiofrequency perforation PV, modified BT shunt, PV dilatation                          Undetermined         1.61
  13[†](#uog19047-note-0004){ref-type="fn"}         PAIVS             23 + 6            2015               3                    23 + 5, 28 + 5                 Partial                0.6                       N                      Y                                            3                                                   1.2                         38 + 2                            PV perforation and dilatation, modified BT shunt and RVPAC, BDG and RVPAC                        1.5 V             1.63
  14                                                 CPS              25 + 1            2015               2                        26 + 2                     Partial                0.9                       N                      Y                                            0                                                   3.4                         38 + 3                                                          PV dilatation                                                        BV              1.64
  15                                                PAIVS             30 + 4            2016               2                        30 + 1                        Y                   0.7                       Y                      Y                                            2                                                   2.9                         38 + 1                                                       PV dilatation (2×)                                                      BV              1.25
  16                                                PAIVS             28 + 3            2016               2                        26 + 4                        Y                   1.1                       Y                      Y                                            2                                                    ND                         38 + 4          PV perforation and dilatation, PDA stent, PV dilatation (2×), spontaneous closure of PDA stent, PV dilatation        BV              1.13
  17                                                PAIVS             27 + 3            2016               1                          ---                         Y                   1.2                       N                      N                                            2                                                   3.7                         38 + 0                                                       PV dilatation (2×)                                                      BV              0.90
  18[†](#uog19047-note-0004){ref-type="fn"}          CPS              30 + 1            2016               1                          ---                         Y                   0.8                       N                      N                                            1                                                   1.3                         33 + 5                                                       PV dilatation (2×)                                                      BV              0.93
  19[†](#uog19047-note-0004){ref-type="fn"}         PAIVS             27 + 4            2016               3                    22 + 3, 26 + 4                 Partial                0.8                       N                      N                                            3                                                   4.0                         39 + 3                                   PV perforation and dilatation, PDA stent and PV dilatation                                  BV              0.78
  20                                                PAIVS             28 + 4            2016               2                        28 + 3                        Y                   ND                        N                      Y                                           ND                                                    ND                         39 + 1                                             Modified BT shunt and RVOT enlargement                                       Undetermined         0.22
  21[†](#uog19047-note-0004){ref-type="fn"}         PAIVS             29 + 1            2017               1                          ---                         Y                   1.1                       N                      N                                            1                                                   2.8                         30 + 4                                                         No intervention                                                       BV             0.1 NND
  22                                                 CPS              28 + 3            2017               1                          ---                         Y                   ND                        N                      Y                                            0                                                   1.6                         35 + 5                                                          PV dilatation                                                        BV              0.24
  23                                                PAIVS             29 + 5            2017               2                        29 + 0                        Y                   1.0                       N                      N                                            3                                                   3.5                         30 + 1                                            On i.v. prostaglandins at last follow‐up                                      Undetermined         0.11

Assessed by four‐point scoring system of Roman *et al*.[15](#uog19047-bib-0015){ref-type="ref"} (criteria: tricuspid/mitral valve annular diameter ratio \< 0.7, RV/LV length ratio \< 0.6, RV filling time \< 31.5% of cardiac cycle length, presence of RV sinusoids) indicating non‐BV circulation after birth for fetuses with score of 3 with 100% sensitivity and 75% specificity.

Patient followed up and treated at our institution. 1.5 V, one‐and‐a‐half ventricle circulation; BDG, bidirectional Glenn anastomosis; BT shunt, Blalock--Taussig shunt; BV, biventricular; GA, gestational age; i.v., intravenous; LFU, lost to follow‐up; LV, left ventricle; N, no; ND, no data available; NND, neonatal death; n.t., necessitating treatment; PDA, persistent ductus arteriosus; PV, pulmonary valve; RPA, right pulmonary artery; RV, right ventricle; RVOT, right ventricular outflow tract; RVPAC, right ventricle‐to‐pulmonary artery conduit; TV, tricuspid valve; UV, univentricular; Y, yes.

Mortality, complications and prematurity {#uog19047-sec-0008}
----------------------------------------

No fetal death occurred. All 23 fetuses were liveborn at a median gestational age of 38 + 2 (range, 30 + 1 to 40 + 4) weeks. Pericardial effusion necessitating treatment occurred in 4/35 (11.4%) and persistent bradycardia in 11/35 (31.4%) procedures.

There were six (26.1%) preterm deliveries, two due to premature rupture of membranes (3 days after intervention at 30 + 2 weeks and 8 weeks after intervention at 33 weeks), one after 3 weeks of intervention due to pre‐eclampsia of the mother and three due to preterm labor between 9 days and 8 + 2 weeks after procedure. Additionally, one neonate was found to have CHARGE syndrome with esophageal atresia.

Immediate changes after fetal pulmonary valvuloplasty {#uog19047-sec-0009}
-----------------------------------------------------

For the 17 fetuses that had successful pulmonary valvuloplasty, all cardiac parameters improved significantly after the intervention (Figure [1](#uog19047-fig-0001){ref-type="fig"}); the most significant change was observed for RV filling time. Cardiac measurements before and after successful intervention are shown in Table [3](#uog19047-tbl-0003){ref-type="table"}. Figure [2](#uog19047-fig-0002){ref-type="fig"} shows change in RV dimensions and improvement of RV filling time with change from a short monophasic to a longer biphasic inflow and Figures [3](#uog19047-fig-0003){ref-type="fig"}a and b illustrate decrease of TR velocity after intervention. Even after a successful intervention, there remained a gradient across the PV in almost all cases (Table [2](#uog19047-tbl-0002){ref-type="table"}). Figure [3](#uog19047-fig-0003){ref-type="fig"}c shows the residual PV gradient with a new pulmonary regurgitation immediately after a successful procedure. Fetuses with a partially successful intervention (*n* = 4) demonstrated improvement in cardiac parameters as well, but not in all parameters (Table [S1](#uog19047-supitem-0001){ref-type="supplementary-material"}).

![Cardiac measurements before and after completely or partially successful fetal pulmonary valve intervention in 21 fetuses with pulmonary atresia with intact ventricular septum or critical pulmonary stenosis. Patients 6 and 23 were excluded from (c) and (e) due to exclusive retrograde filling of right ventricle by severe pulmonary regurgitation. HR, heart rate; RV/LV ratio, right to left ventricular length ratio; TR Vmax, maximum velocity of tricuspid regurgitation; TV/MV ratio, tricuspid to mitral valve annular diameter ratio; TV‐VTI, tricuspid valve velocity time integral.](UOG-52-230-g007){#uog19047-fig-0001}

###### 

Cardiac measurements before and after completely successful intervention in 17 fetuses that underwent fetal pulmonary valvuloplasty for pulmonary atresia with intact ventricular septum or critical pulmonary stenosis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                                 *n* [\*](#uog19047-note-0006){ref-type="fn"}    Value (median (range))                *P*             
  -------------------------------------------------------- ---------------------------------------------- --------------------------- --------------------------- -----------
  RV/LV ratio                                                                    14                           0.57 (0.47 to 0.70)         0.64 (0.58 to 0.75)       0.0001  

  TV/MV ratio                                                                    13                           0.69 (0.62 to 0.83)         0.78 (0.68 to 0.88)       0.0004  

  RV filling time[†](#uog19047-note-0007){ref-type="fn"}                         13                           0.28 (0.19 to 0.42)         0.38 (0.33 to 0.54)       0.000002

  RV length *Z*‐score                                                            13                        --2.95 (--4.64 to --1.33)   --2.08 (--3.85 to --1.09)    0.0005  

  TV annular diameter *Z*‐score                                                  13                        --1.81 (--3.52 to --1.31)   --1.56 (--2.55 to --0.53)    0.0012  

  TR Vmax                                                                        12                           4.88 (3.28 to 5.50)         3.90 (2.74 to 5.38)       0.0008  

  TV‐VTI × HR\                                                                   11                           868 (287.5 to 1859)        1044 (650 to 1687.5)       0.008   
  (cm × bpm)                                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data not available in all cases.

Duration of tricuspid valve (TV) inflow indexed to cardiac cycle length.

HR, heart rate; RV, right ventricular; RV/LV ratio, right to left ventricular length ratio; TR Vmax, maximum velocity of tricuspid regurgitation; TV/MV ratio, tricuspid to mitral valve annular diameter ratio; TV‐VTI, tricuspid valve velocity time integral.

![Apical four‐chamber views of Patient 9 before (a) and 2 days after (b) intervention; arrows mark points of measurement for tricuspid and mitral valve annular diameter and right (RV) and left (LV) ventricular length; note increase in RV length and tricuspid valve diameter after intervention. Pulsed‐wave Doppler traces with RV filling times of Patient 15 before (c) and after (d) intervention; note change from short monophasic RV filling of 25% (107/422 ms) of cardiac cycle length before intervention to longer biphasic RV filling of 39% (197/505 ms) of cardiac cycle length after intervention. LA, left atrium; RA, right atrium; TR, tricuspid regurgitation.](UOG-52-230-g009){#uog19047-fig-0002}

![Continuous‐wave (CW) Doppler traces of tricuspid regurgitation (TR) in Patient 11 before and after intervention; pressure gradient was reduced from 75 mmHg (4.34 m/s) (a) to 49 mmHg (3.50 m/s) (b). (c) CW Doppler tracing of blood flow across pulmonary valve (PV) with remaining antegrade gradient of 49 mmHg and new pulmonary regurgitation (PR) in Patient 9 after intervention (c).](UOG-52-230-g005){#uog19047-fig-0003}

Intrauterine course {#uog19047-sec-0010}
-------------------

Longitudinal data of cases with successful or partially successful intervention were available from five patients who were all delivered and followed up in our institution. Preintervention, immediate postintervention and first postpartum measurements are shown in Figure [4](#uog19047-fig-0004){ref-type="fig"}. The greatest change in RV/LV ratio occurred immediately after the procedure and it continued to increase in three patients, whereas it remained stable in the other two patients. TV/MV ratio after intervention continued to increase in four patients.

![Longitudinal development of right to left ventricular length (RV/LV) ratio (a) and tricuspid to mitral valve annular diameter (TV/MV) ratio (b) in five fetuses that underwent fetal pulmonary valvuloplasty. Plotted are measurements before intervention, immediately after intervention and immediately postpartum, with intervention indicated by asterisks. In Patients 11 and 19, two measurements were performed before intervention. Measurement of TV/MV ratio immediately after intervention is missing for Patient 19 (b). ![](UOG-52-230-g002.jpg "image"), Patient 6; ![](UOG-52-230-g006.jpg "image"), Patient 11; ![](UOG-52-230-g003.jpg "image"), Patient 18; ![](UOG-52-230-g008.jpg "image"), Patient 19; ![](UOG-52-230-g001.jpg "image"), Patient 21.](UOG-52-230-g010){#uog19047-fig-0004}

Progressive PV stenosis during advancing gestation was observed in almost all fetuses and re‐atresia occurred in four patients. Two of those fetuses had a successful intervention at 27 + 5 and 28 + 3 weeks with a balloon‐to‐valve ratio of 0.8 and 1.1, respectively. The remaining two had partially successful interventions at 23 + 6 and 27 + 4 weeks with balloon‐to‐valve ratios of 0.6 and 0.8, respectively.

Postnatal outcome {#uog19047-sec-0011}
-----------------

Postnatal procedures and outcome at last follow‐up for all patients are listed in Table [2](#uog19047-tbl-0002){ref-type="table"}. There were two neonatal deaths, both of which occurred after a preterm delivery. Patient 2 was delivered at 32 weeks following an unsuccessful intervention, and was diagnosed with CHARGE syndrome and died after placement of a BT shunt due to hemodynamic instability. Patient 21 was delivered at 30 + 4 weeks, 9 days after a successful intervention, and was found to have a good sized RV with wide open PV; the arterial duct remained open without prostaglandins and the patient rapidly developed severe necrotizing enterocolitis and died after extensive bowel resection.

All other patients were alive after a median follow‐up of 1.63 (range, 0.10--16.36) years. Freedom from mortality after 1 year was 90.2%. Out of the 21 fetuses with a successful or partially successful procedure, with various prediction scores, 15 (71.4%) became biventricular, three (14.3%) had a one‐and‐a‐half ventricle circulation and three (14.3%) had an undetermined circulation. One infant was still on prostaglandins 6 weeks after a preterm birth at 31 weeks and two patients had a modified BT shunt at the age of 2.6 and 19.3 months. All but one of the neonates needed an early PV intervention and 11 additionally required a systemic‐to‐pulmonary‐artery shunt or a ductal stent in the neonatal period.

Fetuses with predicted non‐biventricular outcome {#uog19047-sec-0012}
------------------------------------------------

The prediction score as described by Roman *et al*.[15](#uog19047-bib-0015){ref-type="ref"} could be calculated for 20 of 23 fetuses (Figure [5](#uog19047-fig-0005){ref-type="fig"}). Of these, 10 (50%) had a score of three, which is considered to predict a non‐biventricular circulation after birth with 100% sensitivity. Six of these 10 patients had a successful intervention, four of which achieved a biventricular circulation and two had an undetermined circulation at the age of 41 days and 1.6 years.

![Circulation outcome in 23 fetuses that underwent fetal pulmonary valvuloplasty according to prediction score by Roman *et al*.[15](#uog19047-bib-0015){ref-type="ref"}, a four‐point scoring system indicating non‐biventricular (BV) circulation after birth for fetuses with score of 3, with 100% sensitivity and 75% specificity. Note that 5/10 patients with predicted non‐BV outcome had BV circulation. 1.5 V, one‐and‐a‐half ventricle circulation; UV, univentricular circulation.](UOG-52-230-g004){#uog19047-fig-0005}

DISCUSSION {#uog19047-sec-0013}
==========

In the absence of major coronary fistulae or muscular atresia of the RV outflow tract, RV and TV size at birth are the major determinants for a biventricular outcome. We have shown that technically successful pulmonary valvuloplasty in second‐ and third‐trimester fetuses with PAIVS or CPS leads to an immediate and significant increase in RV and TV size, decrease in RV pressure and longer and better RV filling. In the five fetuses that were followed up in our institution, we observed that initial cardiac changes were followed by continued growth of RV structures until birth. In more than half of the fetuses with a predicted non‐biventricular outcome and successful procedure, a two‐ventricle circulation was achieved.

In all fetuses with a successful PV intervention, significantly greater RV length and TV diameter were observed 1 to 2 days after the procedure, which has not been described before. We do not believe that real RV or TV growth had occurred in such a short period of time, but we suggest that the decompression of the RV led immediately to improved filling, evidenced by the significantly increased TV‐VTI × HR product, resulting in greater RV volumes. Obviously, RV length had been underestimated before the intervention, because the RV apex was formed by the moderator band. Increased filling after intervention revealed some cavity at the RV apex, which was not visible before. The increase of TV diameter can be explained by better and longer TV opening, which made it easier to measure the full diameter of the valve. This is an important finding, because underestimation of the true RV and TV size may lead to prediction of a poorer outcome resulting in overly pessimistic counseling of the parents. Reduction in RV pressure was also highly significant, as estimated by TR velocity and the lengthening of RV filling time, both logical consequences of establishing and improving forward flow through the PV. Despite being lower than preintervention, RV pressure remained above normal in most cases. We were not able to eliminate completely the gradient across the pulmonary outflow tract, particularly in late gestation, mainly because the available balloons were too small due to the limited inner diameter of the needles we used. In fact, we think that a balloon‐to‐valve ratio of 1.3--1.5 is necessary to perform an optimal pulmonary valvuloplasty. Even when we considered the intervention as only partially successful, immediate improvements could be observed, indicating that even a minor RV decompression is able to improve hemodynamics.

No procedure‐related deaths or intrauterine deaths occurred at our center. Certainly, right heart interventions are better tolerated than are left heart ones, and a key advantage was that all procedures were carried out by an experienced team that had already performed a substantial number of left heart interventions[16](#uog19047-bib-0016){ref-type="ref"}, [17](#uog19047-bib-0017){ref-type="ref"}.

An important question of this study was whether the initial increase in RV size would be followed by natural growth of right heart structures. It has been shown in animal experiments that the fetal myocardium responds with myocyte proliferation, i.e. hyperplasia, to increased pre‐ and afterload[18](#uog19047-bib-0018){ref-type="ref"}, [19](#uog19047-bib-0019){ref-type="ref"}, [20](#uog19047-bib-0020){ref-type="ref"}. The ability for myocyte proliferation is lost shortly after birth and the postnatal myocardium responds with hypertrophy rather than hyperplasia. After neonatal pulmonary valvuloplasty, the RV will grow but only in relation to body size and catch‐up growth does not occur[7](#uog19047-bib-0007){ref-type="ref"}. Our limited longitudinal data provide evidence that, after a period of little or no RV growth, a successful PV intervention could have the potential to restore RV growth towards term, a finding that is in agreement with observations in previous small studies[8](#uog19047-bib-0008){ref-type="ref"}, [10](#uog19047-bib-0010){ref-type="ref"}, [11](#uog19047-bib-0011){ref-type="ref"}. Three out of five fetuses in our cohort even demonstrated a further increase in RV/LV ratio and four of five patients a further increase in TV/MV ratio, indicating that there could even be an additional catch‐up growth of the RV prenatally. We speculate that this RV growth is achieved by myocardial hyperplasia, which would not have been possible after birth. Theoretically, at birth, these RVs should consist of more myocardial cells with a potential for better postnatal adaptation and improved long‐term function.

During advancing gestation, progressive gradients across the PV were observed in almost all fetuses. This could have been due to real re‐stenosis of the dilated PV or related to progressive better RV filling and thus increased flow across the valve (relative stenosis). Re‐atresia of the PV was observed in four fetuses. Two fetuses had only partially successful interventions early in gestation, so the created opening of the PV was obviously too small to stay open until birth. Interestingly, the two other fetuses initially had successful interventions and also developed atresia. It is possible that the balloon‐to‐valve ratios of 0.8 and 1.1 were still too small and this could have been avoided with larger balloons.

In the absence of a valid control group during the same study period, we chose to refer to published criteria for prediction of outcome. Several reports have been published regarding the prediction of a non‐biventricular/univentricular outcome in fetuses with PAIVS/CPS[5](#uog19047-bib-0005){ref-type="ref"}, [11](#uog19047-bib-0011){ref-type="ref"}, [15](#uog19047-bib-0015){ref-type="ref"}, [21](#uog19047-bib-0021){ref-type="ref"}. Using the criteria published by Roman *et al*.[15](#uog19047-bib-0015){ref-type="ref"}, we found that more than half of the patients with a predicted non‐biventricular outcome could achieve a biventricular circulation. This provides evidence that a timely *in‐utero* pulmonary valvuloplasty is able to modify the natural history of fetuses with PAIVS or CPS and increases the likelihood of biventricular circulation after birth. However, as normal RV size could not be achieved even after a successful procedure, it is justified to avoid delaying intervention until the RV becomes severely hypoplastic, and instead perform fetal pulmonary valvuloplasty as soon as possible to allow optimal *in‐utero* recovery.

The most important limitations of this study are its retrospective design, the small number of patients and the non‐standardized postnatal management of the respective referral centers. A further limitation is the lack of a control group of matched fetuses that did not undergo fetal pulmonary valvuloplasty; data published by Roman *et al*.[15](#uog19047-bib-0015){ref-type="ref"} were used instead. Furthermore, reliable longitudinal data were available for only five out of 23 patients; therefore, no significance of continuous RV growth could be calculated, and certainly a greater number of patients would be needed to confirm these observations.

In conclusion, for selected fetuses with PAIVS or CPS, *in‐utero* pulmonary valvuloplasty leads immediately to larger RV caused by reduced afterload and increased filling, thus improving the likelihood of a biventricular outcome.
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**Table S1** Cardiac measurements of four fetuses before and after partially successful fetal pulmonary valvuloplasty
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Click here for additional data file.
